APT20TTMG

APT20TTMG is a synthetic single-stranded cDNA-based RNA therapy developed by APTAH Biosciences using its proprietary RNA WiCo™ technology platform. It is designed to target the U1 small nuclear ribonucleoprotein (U1-snRNP), a critical component of the spliceosome involved in co-transcriptional gene regulation. By binding to U1-snRNP and conserved regions of pre-mRNAs, APT20TTMG facilitates accurate U1-snRNP assembly and prevents premature termination of transcription, thereby restoring correct RNA splicing and function. This mechanism is intended to address U1-snRNP dysfunction, which is implicated in a wide range of sporadic genetic disorders, including various cancers, neurodegenerative diseases, autoimmune conditions, and ophthalmic disorders.